Ij,
MEDX was serious about mAb in-house manufacturing capability from day one. 10 kg is in line as late toxicology/early clinicals quantities requirement. This is very, very big plus for their collaborative customers.
I never understood (and still do not) why is MEDX behind ABGX in MC (1.4 billions difference).
I own both.
Miljenko
PS: Today ABGX/J&J news:
Abgenix Expands Antibody Agreement With Centocor
FREMONT, Calif.--(BUSINESS WIRE)--June 7, 2001--Abgenix, Inc. (Nasdaq:ABGX - news) announced today that it has expanded its research collaboration agreement with Centocor Inc.
Under the expanded agreement, Centocor will use Abgenix's XenoMouse(TM) technology to generate fully human monoclonal antibody therapies against multiple antigen targets in various disease indications. The original agreement between the parties was signed in December 1998.
As under the terms of the original agreement, Abgenix will receive research license fees, and could receive milestone payments and royalties on any future product sales by Centocor. Centocor will be responsible for product development, manufacturing, and commercialization of any products developed through the collaboration.
``We are pleased to expand our relationship with Centocor, a world leader in the commercialization of antibody products,'' stated R. Scott Greer, chairman and chief executive officer of Abgenix. ``Centocor is the eighth collaborator to expand their access to our XenoMouse technology.'' |
